TTF-1
in extra-pulmonary adenocarcinoma (excluding thyroid neoplasms)
|
Breast |
0/141 (0/965, 0/1815,
0/5 (signet
ring cell carcinomas)19,
0/7
(metastases to brain)23,
0/534, 0/10(using
monoclonal 8G7G3/1)6), 0/13(using
clone 8G7G3/1)7, 0/8(cell
blocks from cases with metastatic adenocarcinoma to serous cavities,
using clone 8G7G3/1)9, 0/51(using
a polyclonal antibody)1, 0/2(lung
metastasis, using clone 8G7G3/1)8,
0/25(using
clone 8G7G3/1)35 |
|
Salivary gland |
0/3
(metastases to brain)23 |
|
Oesophagus |
0/315 |
|
Stomach |
1/98 (1/661, 0/315,
0/519, 0/2431),
0/2(using
clone 8G7G3/1)7, 0/9(cell
blocks from cases with metastatic adenocarcinoma to serous cavities,
using clone 8G7G3/1)9 |
|
Colon |
0/230 (0/18
(primary tumours, using polyclonal antibody)1,
0/21 (primary
tumours, using clone8G7G3/1)2, 0/30(primary
tumours, using clone8G7G3/1)4 , 0/20(primary
tumours, using clone 8G7G3/1)6,
0/26(primary
tumours, using clone 8G7G3/1)7,
0/3(lung
metastasis, using clone 8G7G3/1)8,
0/8(cell
blocks from cases of metastatic carcinoma to serous cavities, using
clone 8G7G3/1)9, 0/6(lung
metastasis, using clone 8G7G3/1)10,
0/5(lung
metastasis, using clone 8G7G3/1)11,
0/26(lung
metastasis, using clone 8G7G3/1)12,
0/519, 0/1(metastases
to brain)23,
0/3531, 0/1634), 0/10(using
clone 8G7G3/1)35 |
|
Liver |
0/22(using
monoclonal 8G7G3/1)6, 0/2(lung
metastasis, using clone 8G7G3/1)8 |
|
Gallblader |
0/115 |
|
Pancreas |
0/9 (0/215,
0/731) |
|
Kidney |
0/41 (0/185, 0/14
(metastases to brain)23,
0/934), 0/7(using
clone 8G7G3/1)7, 0/8(using
a polyclonal antibody)1, 0/2(lung
metastasis, using clone 8G7G3/1)8,
0/10(using
clone 8G7G3/1)35 |
|
Ovary |
16/116 (0/305, 1/16
(few very weakly reactive cells)15,
0/1531, 15/53
(endometrioid: 3/8, serous: 6/25; strong in one case, clear cell: 4/10;
strong in two cases, mucinous: 2/10; strong in one case)33,
0/234), 0/15(cell
blocks from cases with metastatic adenocarcinoma to serous cavities,
using clone 8G7G3/1)9, 0/4(lung
metastasis, using clone 8G7G3/1)8,
0/30(using
clone 8G7G3/1)35 |
|
Endometrium |
1/40 (1/81, 0/415,
0/2531, 0/334), 0/1(using
monoclonal 8G7G3/1)6, 0/6(lung
metastasis, using clone 8G7G3/1)8 |
|
Prostate |
0/21 (0/195, 0/215),
0/9(using a
polyclonal antibody)1, 0/1(lung
metastasis, using clone 8G7G3/1)8,
0/10(using
clone 8G7G3/1)35 |
|
Total |
18/534 (2/2865,
1/4915,
0/1519,
0/2523,
0/10631, 15/5333) |
15†using
cell blocks from FNAs
I have seen one focally positive colorectal
metastasis to lung., unpublished case.
References
2Holzinger
A, Dingle S, Bejarano PA, et al. Monoclonal antibody to thyroid
transcription factor-1: production, characterization, and usefulness
in tumor diagnosis. Hybridoma 1996; 15:49-53
3 Ordonez
NG. Value of thyroid transcription factor-1 immunostaining in
distinguishing small cell lung carcinomas from other small cell
carcinomas. Am J Surg Pathol 2000; 24:1217-23
4 Kaufmann
O,Dietel M Thyroid transcription factor-1 is the superior
immunohistochemical marker for pulmonary adenocarcinomas and large
cell carcinomas compared to surfactant proteins A and B.
Histopathology 2000; 36:8-16
5 Ordonez
NG. Thyroid transcription factor-1 is a marker of lung and thyroid
carcinomas. Advances in Anatomic Pathology 2000; 7(2): 123-127.
6 Chang
YL, Lee YC, Liao WY, et al. The utility and limitation of thyroid
transcription factor-1 protein in primary and metastatic pulmonary
neoplasms. Lung Cancer 2004; 44:149-57
7 Moldvay
J, Jackel M, Bogos K, et al. The role of TTF-1 in differentiating
primary and metastatic lung adenocarcinomas. Pathol Oncol Res 2004; 10:85-8
8 Reis-Filho
JS, Carrilho C, Valenti C, et al. Is TTF1 a good immunohistochemical
marker to distinguish primary from metastatic lung adenocarcinomas?
Pathol Res Pract 2000; 196:835-40
9 Jang
KY, Kang MJ, Lee DG, et al. Utility of thyroid transcription
factor-1 and cytokeratin 7 and 20 immunostaining in the
identification of origin in malignant effusions. Anal Quant Cytol
Histol 2001; 23:400-4
10 Chhieng
DC, Cangiarella JF, Zakowski MF, et al. Use of thyroid transcription
factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between
primary lung carcinomas and metastatic lesions in fine-needle
aspiration biopsy specimens. Cancer 2001; 93:330-6
11 Ng
WK, Chow JC,Ng PK Thyroid transcription factor-1 is highly sensitive
and specific in differentiating metastatic pulmonary from
extrapulmonary adenocarcinoma in effusion fluid cytology specimens.
Cancer 2002; 96:43-8
12 Wieczorek
TJ, Pinkus JL, Glickman JN, et al. Comparison of thyroid
transcription factor-1 and hepatocyte antigen immunohistochemical
analysis in the differential diagnosis of hepatocellular carcinoma,
metastatic adenocarcinoma, renal cell carcinoma, and adrenal cortical
carcinoma. Am J Clin Pathol 2002; 118:911-21
15 Hecht,
J. L., Pinkus, J. L., Weinstein, L. J., Pinkus, G. S. The value of
thyroid transcription factor-1 in cytologic preparations as a marker
for metastatic adenocarcinoma of lung origin Am J Clin Pathol 2001;116:483-488.
19 Merchant,
S.H., Amin, M.B., Tamboli, P., Ro, J., Ordonez, N.G., Ayala, A.G.,
Czerniak, B.A. and Ro, J.Y. Primary signet-ring cell carcinoma of
lung: immunohistochemical study and comparison with non-pulmonary
signet-ring cell carcinomas. Am J Surg Pathol 2001;25:1515-9.
23 Srodon,
M. and Westra, W.H. Immunohistochemical staining for thyroid
transcription factor-1: a helpful aid in discerning primary site of
tumor origin in patients with brain metastases. Hum Pathol 2002;33:642-5.
31 Stenhouse,
G., N. Fyfe, et al. (2004). "Thyroid transcription factor 1 in
pulmonary adenocarcinoma." J Clin Pathol 57(4): 383-7.
33 Quddus
MR et al. Expression of TTF-1 in primary ovarian surface epithelial
carcinomas: a study of 53 cases. Modern Pathology 2004 17(1):211A.
34 Jerome
Marson, V., J. Mazieres, et al. (2004). "Expression of TTF-1
and cytokeratins in primary and secondary epithelial lung tumours:
correlation with histological type and grade." Histopathology
45(2): 125-34.
35 Ordonez
NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1,
and CD44S immunostaining in distinguishing epithelial pleural
mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am J
Surg Pathol 2000; 24:598-606.
This page last revised30.7.2004.
©SMUHT/PW Bishop